NTHI earnings analysis
What we found in NTHI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied filing extract does not include the Q2 income statement, balance sheet, or cash-flow statement, so revenue, margins, EPS, cash, debt, working capital, and free cash flow cannot be quantified. The company raised $7.0 million in equity capital and eliminated a $737,921 Fox Infused settlement, but still reported ineffective disclosure controls and an unpaid OEP settlement payable of $4,378,904. No quantitative guidance was provided, and the filing states that the material risk factors were unchanged from the prior Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Raised $7.0M in Equity Capital
- The company raised $7.0 million during the quarter: $2.0 million from an April common-stock and warrant private placement and $5.0 million from June issuance of 6,000 Series A Convertible Preferred shares.
- Cleared Fox Infused Obligation
- NeOnc paid the Fox Infused settlement in full in February 2026, including accrued interest, for a total payment of $737,921; no related liability remained as of June 30, 2026.
- Expanded Control-Remediation Program
- Management initiated remediation measures including a new NetSuite ERP implementation, an information-technology controls consultant, a formal related-party transaction policy, and hiring a Chief Accounting Officer.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Internal-Control Weaknesses Persist
- Management concluded that disclosure controls were not effective as of June 30, 2026 because of material weaknesses spanning segregation of duties, entity-level controls, significant transaction classes, related-party transaction controls, and information-technology user access.
- $4.38M Unpaid OEP Settlement
- The OEP litigation settlement payable increased to $4,378,904 at June 30, 2026 from $4,170,000 at December 31, 2025, and the company had not paid the settlement as of the filing date.
- Equity Dilution and Insider Selling Risk
- The April financing issued 277,777 common shares and warrants for 277,777 additional shares at a $9.00 exercise price, while directors and officers adopted trading plans covering up to 190,000 shares in June 2026, creating potential dilution and selling pressure.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the filing. The filing states that no material risk-factor changes occurred versus the December 31, 2025 Form 10-K.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- NeOnc Technologies Holdings, Inc. reported zero revenue for Q4 2025, continuing the trend of significant operational challenges. The net loss for the quarter was $8,819,932, an improvement from a loss of $32,326,016 in…
- 10-K · May 5, 2026
- NeOnc Technologies Holdings, Inc. reported significant operating challenges in 2025, highlighted by zero revenue in Q4 and a diluted EPS loss of -0.72. The company is focused on preclinical trials and aims to address…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NTHI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever